A B S T R A C T An endothelial cell-associated cofactor that greatly enhances the rate of protein C activation by thrombin has recently been described. The observation that the cofactor binds thrombin with unusually high affinity (Kd = 0.5 nM) suggested that low level thrombin infusion into dogs might lead to the selective activation of protein C.
Infusion of thrombin (1 U/min per kg body wt) into the jugular vein of dogs leads to the formation of a systemic anticoagulant activity within 5 min of starting the infusion. The plasma has a prolonged partial thromboplastin time and Factor Xa clotting time, but there is no change in the thrombin clotting time. The systemic anticoagulant activity is identified as activated protein C for the following reasons: (a) anti-canine activated protein C IgG antibodies inhibit the anticoagulant activity; (b) the anticoagulant activity can be partially purified from the plasma of dogs infused with thrombin by barium citrate adsorption; (c) the anticoagulant has chromatographic properties on QAE Sephadex indistinguishable from those of activated protein C, and (d) the rate at which this anticoagulant is inhibited in citrated canine plasma is identical to that of canine activated protein C. The in vivo activation of protein C appears to be receptor mediated since it occurs at low thrombin concentration and since it can be progressively inhibited by simultaneous infusion of diisopropylphospho-thrombin with thrombin. The activation of protein C at low levels of thrombin is selective, since neither the platelet count nor the Factor V levels are altered. Thrombin infusion leads to an elevation in circulating plasminogen activator levels. This appears to be mediated through the activation of protein C since coinfusion of diisopropylphospho-thrombin with thrombin inhibits the increase in plasminogen activator levels. Pretreatment of dogs with dicumarol blocks both the formation of anticoagulant activity and the rise in plasminogen activator. When the dicumarol-treated dogs are supplemented with isolated protein C and thrombin is in-INTRODUCTION Protein C is a vitamin K-dependent plasma protein (1) . The activated form of the protein, protein Ca, exhibits a potent (2, 3) and highly specific anticoagulant effect expressed through the selective inactivation of clotting Factors V (4, 5) and VIII (5, 6) . The activated forms of these clotting factors are especially susceptible to inactivation by protein Ca (6) (7) (8) . Phospholipid and Ca2' accelerate the inactivation of Factor Va and VIIIa by protein Ca (4) (5) (6) (7) (8) (9) . Protein Ca also generates fibrinolytic activity in blood both in vitro (10) (11) (12) and in vivo (13) (14) . The in vivo effects are mediated, at least in part, by increased levels of circulating plasminogen activator (14) . Thus, the properties of activated protein C suggest an important role for protein C in the regulation of both clot formation and clot lysis.
Recent studies have implicated protein C in human disease. Marlar and Griffin (15) have shown that patients lacking an inhibitor to activated protein C exhibit simultaneous Factor V and Factor VIII deficiency. A family has now been described with recurrent thrombosis and low levels of protein C antigen (16) . Both of these studies further support the hypothesis that protein C plays a central role in control of clot formation.
Expression of either the anticoagulant (5, 7, 8) or the fibrinolytic activity (14) of protein C requires the activation of protein C. Little or no protein C is activated during blood clotting (17) and depletion of protein C has no effect on in vitro clotting assays (18) . Direct activation of protein C by thrombin occurs, but the rate of activation is too slow to be physiologically significant (17, 19, 20 ). An endothelial cell-associated cofactor, which binds thrombin with high affinity and enhances protein C activation at least 20,000-fold, has been identified (21, 22) and isolated (23) . The existence of a high affinity receptor for thrombin that accelerates protein C activation provides a plausible mechanism for activation of protein C in vivo. We have now demonstrated that low level thrombin infusion leads to the selective activation of protein C in vivo.
METHODS
Reagents. Bovine blood was the generous gift of the Cornett Packing Company, Oklahoma City, OK. Reagents were purchased from sources previously recorded (14) ; all were of the highest grade commercially available.
Protein and thrombin preparation. Bovine and canine thrombin were isolated following activation of the purified prothrombin with purified Factor X. (24) , Factor Va (25), phospholipid, and Ca21 (24) . For some experiments thrombin was inactivated with 1 mM diisopropylfluorophosphate, dialyzed to remove excess reagent, and used within 48 h.
Protein C preparation. Bovine protein C and activated protein C were purified as described previously (26) . Canine protein C and activated protein C were purified using the methods described for the isolation of the bovine proteins (26) . Preparation of canine prothrombin complex. To prepare the canine prothrombin complex, pooled citrated canine plasma containing 2 mM benzamidine was used and the prothrombin complex was partially purified by barium citrate adsorption, sodium citrate wash, and EDTA elution (27) . The partially purified complex was treated with diisopropylfluorophosphate (2 mM final concentration) and dialyzed extensively against 20 mM Tris buffer, pH 7.4, containing 150 mM NaCI. The Assay of activated protein C. The Factor Xa one-stage clotting time was performed as described previously (7) and used to detect protein Ca. The concentration of Factor Xa was adjusted to give a clotting time of 30 s in the control plasma (-6 ng/ml). The level of circulating activated protein C was estimated by reference to a standard curve, which related the prolongation of the Factor Xa one-stage clotting time to the concentration of added, purified activated protein C (Fig. 1 ). Protein C was assayed in partially purified samples by activation of the protein C with thrombin followed by selectively inactivating the thrombin with excess antithrombin III (21) . The activated protein C was then detected using the clotting assay described above.
Levels of circulating lysine-adsorbable plasminogen activator were measured as described previously (29) . Factor V was assayed as previously described (25 (Fig. 2) . A marked prolongation of the Factor Xa onestage clotting time occurred following initiation of the thrombin infusion. When the thrombin was stopped, the prolonged clotting times returned to the base line.
Coagulation studies were initiated to determine if the prolonged clotting times were in response to formation of activated protein C (Fig. 3) . Thrombin infusion at these levels did not influence the thrombin time suggesting that the anticoagulant activity was expressed at the level of prothrombin activation. The possibility that the plasma anticoagulant was activated protein C was examined using antibodies directed against canine protein C. When canine plasma obtained during thrombin infusion was preincubated with antibodies against canine protein C, the prolongation of the Factor Xa clotting time was corrected.
To further document that protein Ca was being formed during the thrombin infusion, partial chromatographic characterization of the anticoagulant was undertaken. Anticoagulant activity was recovered from a barium citrate eluate of plasma obtained following thrombin infusion (Methods). When the barium citrate eluate was chromatographed on QAE-Sephadex, the anticoagulant activity was detected in the trailing shoulder of the prothrombin peak at the position where protein C elutes (Fig. 4) . Protein Ca activity was present in the eluate of the postinfusion plasma, but not in the eluate originating from the prethrombin infusion plasma. One unusual characteristic of protein Ca is that the inhibition of the enzyme in plasma is unusually slow and dependent on a unique plasma protease inhibitor (15) . To characterize the anticoagulant activity further, the rate of inactivation of purified activated protein C in canine plasma was compared with the rate of disappearance of the anticoagulant activity formed minutes FIGURE 2 Thrombin infusion into dogs. Thrombin was infused into three anesthetized dogs through the jugular vein at a rate of 1 U/kg body wt per min over a 20-min period. Prolongation of the Factor X. clotting time was monitored. Similar results were observed in eight other animals.
Activation of Protein C In Vivo 129 The infusion of thrombin at this level had no effect on blood pressure, pulse rate, or body temperature. Animals had no evidence of bleeding during or following thrombin infusion. Autopsy of one animal immediately following thrombin infusion showed no evidence of fibrin deposition in brain, heart, lungs, liver, or kidneys.
Clearance of activated protein C. Since protein Ca anticoagulant activity following thrombin infusion could be detected systemically, it appeared that the protein was cleared slowly from the circulation. To estimate the clearance rate of protein Ca, the disappearance of the anticoagulant activity and of 125I-protein Ca was followed (Fig. 7) . The labeled protein was cleared at the same rate as the anticoagulant activity. The clearance rate of the purified protein was similar to the time course of disappearance of the anticoagulant activity following cessation of the thrombin infusion (Fig. 2) .
Inhibition of protein C activation by DIP-thrombin. The activation of protein C by a complex between thrombin and the endothelial cell cofactor can be inhibited in a dose-dependent fashion by diisopropylfluorophosphate-inhibited thrombin (DIP-thrombin) (21, 22) . If the activation of protein C in vivo was catalyzed by a similar thrombin-cofactor complex, then it follows that coinfusion of increasing levels of DIP-thrombin should progressively block protein C activation. Progressive inhibition of protein C activation was observed as the ratio of DIP-thrombin/ thrombin was increased (Fig. 8) . At Effect of anticoagulants on protein C activation. Oral dicumarol is known to lower the levels of the functional vitamin K-dependent clotting proteins. We expected that the levels of protein C would also be lowered and that the generation of anticoagulant activity due to protein Ca would be inhibited. To test this possibility a series of dogs were anticoagulated with dicumarol (Fig. 9) . Anticoagulation with dicumarol blocked the generation of functionally active protein Ca during thrombin infusion (middle panel). Supplementation of these animals with the vitamin Kdependent plasma proteins (including protein C) restored the response to thrombin infusion. We also wished to determine if protein C alone was sufficient to restore the response to thrombin or whether other vitamin K-dependent proteins, such as protein S, were The relationship between thrombin-induced protein C activation and the elevation of plasminogen activator levels. In Fig. 6 it is apparent that thrombin infusion led to increases in the level of circulating plasminogen activator. In 10 dogs infused with thrombin for 20 min as described in Fig. 2 Fig. 10 .
The observation that protein C is activated before significant Factor V activation (Fig. 6 ) is a reversal of the normal substrate preference exhibited by thrombin. In vitro, thrombin activation of Factor V in plasma is much more rapid than activation of protein C (17 The anticoagulant response observed upon thrombin infusion decays slowly. The time course of disappearance of the anticoagulant activity in vivo closely resembles the time course of disappearance of activated protein C. The similarity of these two curves suggest that the slow return to control levels is dependent primarily on the slow inactivation of activated protein C. If the protein C activation complex were exceptionally stable, then the apparent disappearance of the in vivo anticoagulant activity would be much slower than that seen following direct administration of protein Ca. Accurate estimation of the stability of the protein C activation complex in vivo will require additional experiments and new approaches.
The observation that thrombin can elevate plasminogen activator is not new (30) . However, the studies described here imply that the elevation of circulating plasminogen activator may be closely coupled and/or dependent on the activation of protein C. Two independent observations support this conclusion. DIPthrombin, which blocks protein C activation in vivo, also blocks elevation of plasminogen activator. Since DIP-thrombin does not block direct activation of substrates such as fibrinogen or Factor V,2 it appears that the increase in plasminogen activator is either dependent on protein C activation or on some other receptormediated process involving thrombin. Support for the concept that protein C is involved comes from the observation that dicumarol blocks the increase in plasminogen activator levels. Supplementation with isolated protein C corrects the inability of the animal to increase plasminogen activator levels in response to thrombin. Thus, elevation of plasminogen activator levels in response to low level thrombin infusion ap- 2 Esmon, C. T., Esmon, N. L., and Harris, K. W. 1982.
Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and Factor V activation. Submitted for publication. pears to be both receptor mediated and dependent on a normal vitamin K status. Since activated protein C can elevate circulating plasminogen activator in the absence of added thrombin (14) , it would appear likely that protein C activation in response to thrombin may be an important link between the coagulation system and the fibrinolytic system.
